Antisense of Survivin Inhibits Cervical Cancer Growth in Mice

Overview

Journal Arch Med Sci

Specialty General Medicine

Date 2019 Oct 2

PMID 31572483

Citations 2

Authors

Hui Xu

Tingting Liang

Yongxia Yang

Yanlei Dong

Lin Zhu

Affiliations

Soon will be listed here.

Abstract

Introduction: It is proposed that survivin plays a critical role in the pathogenesis of cancer. Immune regulatory cells are associated with the growth of cancer in the body. Antisenses for the key molecules can suppress tumor growth. This study tests the hypothesis that the antisense of survivin can inhibit cervical cancer.

Results: The results showed that human cervical cancer cells expressed high levels of survivin. The levels of survivin in cervical cancer positively correlated with the frequency of interleukin (IL)-10-producing B cells (B10 cells) in the cancer tissue. Survivin increased the expression of IL-10 in B cells. Exposure to survivin antisense efficiently decreased IL-10 expression in B cells. Administration of antisense of survivin inhibited cervical cancer growth and reduced the frequency of B10 cells in tumor-bearing mice.

Conclusions: The results suggest that the survivin antisense has the potential to be used in the treatment of cervical cancer.

Citing Articles

Prognostic and clinicopathological significance of survivin in gynecological cancer.

Chuwa A, Mvunta D Oncol Rev. 2024; 18:1444008.

PMID: 39687493 PMC: 11646728. DOI: 10.3389/or.2024.1444008.

Licochalcone A inhibits EGFR signalling and translationally suppresses survivin expression in human cancer cells.

Gao F, Li M, Yu X, Liu W, Zhou L, Li W J Cell Mol Med. 2020; 25(2):813-826.

PMID: 33247550 PMC: 7812290. DOI: 10.1111/jcmm.16135.

References

Chen X, Duan N, Zhang C, Zhang W . Survivin and Tumorigenesis: Molecular Mechanisms and Therapeutic Strategies. J Cancer. 2016; 7(3):314-23. PMC: 4747886. DOI: 10.7150/jca.13332. View

Li H, Wu X, Cheng X . Advances in diagnosis and treatment of metastatic cervical cancer. J Gynecol Oncol. 2016; 27(4):e43. PMC: 4864519. DOI: 10.3802/jgo.2016.27.e43. View

Gray M, Gray D . Regulatory B cells mediate tolerance to apoptotic self in health: implications for disease. Int Immunol. 2015; 27(10):505-11. DOI: 10.1093/intimm/dxv045. View

Ryan B, ODonovan N, Duffy M . Survivin: a new target for anti-cancer therapy. Cancer Treat Rev. 2009; 35(7):553-62. DOI: 10.1016/j.ctrv.2009.05.003. View

Siewe B, Stapleton J, Martinson J, Keshavarzian A, Kazmi N, Demarais P . Regulatory B cell frequency correlates with markers of HIV disease progression and attenuates anti-HIV CD8⁺ T cell function in vitro. J Leukoc Biol. 2013; 93(5):811-8. PMC: 3629440. DOI: 10.1189/jlb.0912436. View

Bourgioti C, Chatoupis K, Moulopoulos L . Current imaging strategies for the evaluation of uterine cervical cancer. World J Radiol. 2016; 8(4):342-54. PMC: 4840192. DOI: 10.4329/wjr.v8.i4.342. View

Todo Y, Watari H . Concurrent chemoradiotherapy for cervical cancer: background including evidence-based data, pitfalls of the data, limitation of treatment in certain groups. Chin J Cancer Res. 2016; 28(2):221-7. PMC: 4865615. DOI: 10.21147/j.issn.1000-9604.2016.02.10. View

Tsikouras P, Zervoudis S, Manav B, Tomara E, Iatrakis G, Romanidis C . Cervical cancer: screening, diagnosis and staging. J BUON. 2016; 21(2):320-5. View

Lee H, Kang Y, Ju W . Cervical Cancer Screening in Developing Countries: Using Visual Inspection Methods. Clin J Oncol Nurs. 2016; 20(1):79-83. DOI: 10.1188/16.CJON.79-83. View

10.

Garg H, Suri P, Gupta J, Talwar G, Dubey S . Survivin: a unique target for tumor therapy. Cancer Cell Int. 2016; 16:49. PMC: 4917988. DOI: 10.1186/s12935-016-0326-1. View

11.

Siewe B, Wallace J, Rygielski S, Stapleton J, Martin J, Deeks S . Regulatory B cells inhibit cytotoxic T lymphocyte (CTL) activity and elimination of infected CD4 T cells after in vitro reactivation of HIV latent reservoirs. PLoS One. 2014; 9(4):e92934. PMC: 3989168. DOI: 10.1371/journal.pone.0092934. View

12.

Zhang Y, Morgan R, Podack E, Rosenblatt J . B cell regulation of anti-tumor immune response. Immunol Res. 2013; 57(1-3):115-24. DOI: 10.1007/s12026-013-8472-1. View

13.

Zhang Y, Eliav Y, Shin S, Schreiber T, Podack E, Tadmor T . B lymphocyte inhibition of anti-tumor response depends on expansion of Treg but is independent of B-cell IL-10 secretion. Cancer Immunol Immunother. 2012; 62(1):87-99. PMC: 11029618. DOI: 10.1007/s00262-012-1313-6. View

14.

Dai K, Huang L, Chen J, Yang L, Gong Z . Amphiregulin promotes the immunosuppressive activity of intrahepatic CD4 regulatory T cells to impair CD8 T-cell immunity against hepatitis B virus infection. Immunology. 2014; 144(3):506-517. PMC: 4557687. DOI: 10.1111/imm.12400. View

15.

Manders D, Moron A, McIntire D, Miller D, Richardson D, Kehoe S . Locally Advanced Cervical Cancer: Outcomes With Variable Adherence to Treatment. Am J Clin Oncol. 2016; 41(5):447-451. DOI: 10.1097/COC.0000000000000300. View

16.

Chanthavilay P, Mayxay M, Phongsavan K, Marsden D, White L, Moore L . Accuracy of Combined Visual Inspection with Acetic Acid and Cervical Cytology Testing as a Primary Screening Tool for Cervical Cancer: a Systematic Review and Meta-Analysis. Asian Pac J Cancer Prev. 2015; 16(14):5889-97. DOI: 10.7314/apjcp.2015.16.14.5889. View

17.

Xie Y, Zhang X, Zhao T, Li W, Xiang J . Natural CD8⁺25⁺ regulatory T cell-secreted exosomes capable of suppressing cytotoxic T lymphocyte-mediated immunity against B16 melanoma. Biochem Biophys Res Commun. 2013; 438(1):152-5. DOI: 10.1016/j.bbrc.2013.07.044. View

18.

Abdin A, Soliman N, Saied E . Effect of propranolol on IL-10, visfatin, Hsp70, iNOS, TLR2, and survivin in amelioration of tumor progression and survival in Solid Ehrlich Carcinoma-bearing mice. Pharmacol Rep. 2014; 66(6):1114-21. DOI: 10.1016/j.pharep.2014.07.010. View

19.

Zhu H, Luo H, Shen Z, Hu X, Sun L, Zhu X . Transforming growth factor-β1 in carcinogenesis, progression, and therapy in cervical cancer. Tumour Biol. 2016; 37(6):7075-83. DOI: 10.1007/s13277-016-5028-8. View

20.

Athanasoula K, Gogas H, Polonifi K, Vaiopoulos A, Polyzos A, Mantzourani M . Survivin beyond physiology: orchestration of multistep carcinogenesis and therapeutic potentials. Cancer Lett. 2014; 347(2):175-82. DOI: 10.1016/j.canlet.2014.02.014. View